Trials / Withdrawn
WithdrawnNCT05177276
Selinexor Combination Ph 1 Study
An Investigator Sponsored Phase I/II Study of Selinexor in Combination With Irinotecan in Adults With Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Martin Gutierrez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor | |
| DRUG | Irinotecan |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2022-01-04
- Last updated
- 2022-01-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05177276. Inclusion in this directory is not an endorsement.